Developing new treatments for kids with arthritis is challenging. Drugs that work for adults may not work the same way in children. Ask any pediatrician and they will remind you that kids are not just small adults. Children are still growing and developing. They are different sizes and at different stages of development, which makes dosing and safety considerations more challenging. The types of additional medical conditions children experience may be very different from the conditions seen in adults. Continue reading Developing New Treatments for Kids With Arthritis
Major depression is not uncommon in people with rheumatoid arthritis (RA) – different studies have pegged the number at between 17 percent and 40 percent – but the drugs used to treat RA do little to alleviate depression, according to a systematic review presented at the 2017 British Society for Rheumatology annual conference in Birmingham, United Kingdom.
Continue reading Arthritis Drugs Help Physical Symptoms More Than Disease-Related Depression
Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), is now covered by Medicare and Medicaid. Approved by the Food and Drug Administration in April 2016, Inflectra is the first biosimilar indicated for the treatment of rheumatic and inflammatory diseases to come to market in the United States. The Centers for Medicare and Medicaid Services added it to its pricing list beginning January 1, 2017.